A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination With Nivolumab Plus Ipilimumab in Patients With Renal Cell Carcinoma Previously Treated With Nivolumab Plus Ipilimumab
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2018
At a glance
- Drugs Entinostat (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 06 Sep 2018 Planned End Date changed from 1 Jun 2020 to 1 Aug 2020.
- 06 Sep 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2019.
- 06 Sep 2018 Status changed from not yet recruiting to recruiting.